588,083 Bristol Myers Squibb Company $BMY Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 25.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,716,740 shares of the biopharmaceutical company’s stock after selling 588,083 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Bristol Myers Squibb were worth $107,125,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp raised its position in shares of Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Independent Franchise Partners LLP boosted its position in shares of Bristol Myers Squibb by 1.0% during the 4th quarter. Independent Franchise Partners LLP now owns 20,828,148 shares of the biopharmaceutical company’s stock worth $1,123,470,000 after acquiring an additional 204,797 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $59.34 on Thursday. The business has a 50-day simple moving average of $63.72 and a two-hundred day simple moving average of $60.28. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market cap of $121.22 billion, a PE ratio of 13.07, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the business earned $1.46 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.70 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress provided the main catalyst. Bristol Myers reported favorable Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The data may support upcoming regulatory discussions and strengthen the company’s growth outlook as older blockbuster drugs face competitive pressure. What Could Bristol Myers Squibb BMY Two Phase 3 Wins Change?
• Positive Sentiment: Analyst support remains a tailwind. Truist Financial maintained its Buy rating on BMY, signaling confidence in the company’s pipeline and valuation. Bristol Myers’ relatively low earnings multiple and sizeable dividend yield may also attract income-oriented investors. Truist Financial Sticks to Its Buy Rating for Bristol Myers Squibb
• Neutral Sentiment: Admilparant results were characterized inconsistently. Reports described the Phase 3 idiopathic pulmonary fibrosis data as either positive or mixed, with favorable efficacy and safety observations but some limitations that could affect regulatory expectations. The conflicting interpretation makes the drug a potential opportunity but not yet a clear near-term catalyst. BMY Reports Mixed Phase III Trial Results
• Neutral Sentiment: Investor attention is elevated ahead of quarterly earnings. BMY is scheduled to report third-quarter results later this month, with analysts expecting a single-digit decline in earnings. Recent trial news and the stock’s strong longer-term performance have increased focus on whether results and guidance can support the valuation. Bristol Myers Squibb Quarterly Earnings Preview
• Negative Sentiment: Wells Fargo reduced its price target from $65 to $60 and kept an Equal Weight rating. The lower target reflects limited perceived upside and highlights ongoing concerns about earnings growth, patent-related pressure and the need for newer medicines to replace aging blockbusters. Wells Fargo Lowers Bristol Myers Squibb Price Target

Analyst Ratings Changes

A number of research analysts recently issued reports on BMY shares. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, August 5th. Morgan Stanley restated an “underweight” rating and set a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Zacks Research raised Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 23rd. Royal Bank Of Canada raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Finally, Leerink Partners cut Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $73.00 to $59.00 in a report on Monday, October 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus price target of $64.88.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.